Can-Fite BioPharma (TASE:CANF) - Cotización, noticias y análisis

Resumen de acción CANF

Análisis fundamental de CANF
Puntuación del snowflake
Valoración	2/6
Crecimiento futuro	2/6
Rendimiento pasado	0/6
Salud financiera	5/6
Dividendos	0/6

Recompensas

Cotiza un 99.8% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los ingresos de 67.16%

Los beneficios han crecido un 7.8% al año en los últimos 5 años

Análisis de riesgos

Alta volatilidad del precio de la acción en los últimos 3 meses

Los accionistas han sido diluidos sustancialmente en el último año

Tiene unos ingresos inferiores a 1 millón de dólares ($667K)

No tiene una capitalización de mercado significativa (₪53M)

+ 1 riesgos adicionales

Competidores de Can-Fite BioPharma Ltd.

Evogene

TASE:EVGN

₪32.5m

Kamada

TASE:KMDA

₪1.3b

BioLineRx

TASE:BLRX

₪128.4m

Univo Pharmaceuticals

TASE:UNVO

₪2.8m

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de Can-Fite BioPharma
Precios históricos de las acciones
Precio actual de la acción	₪0.026
Máximo en las últimas 52 semanas	₪0.056
Mínimo de 52 semanas	₪0.025
Beta	0.57
1Cambio en 1 mes	-25.71%
Variación en 3 meses	-16.13%
Cambio de 1 año	-3.70%
3Variación en 3 años	-80.30%
Variación en 5 años	-91.16%
Variación desde la OPV	-99.92%

Noticias y actualizaciones recientes

Recent updates

It's Unlikely That Can-Fite BioPharma Ltd.'s (TLV:CANF) CEO Will See A Huge Pay Rise This Year

Jun 19

Rentabilidad de los accionistas

	CANF	IL Biotechs	Mercado IL
7D	-3.7%	-2.8%	0.8%
1Y	-3.7%	-8.2%	22.8%

Rentabilidad vs. Industria: CANF superó a la industria IL Biotechs, que obtuvo un rendimiento del -8.2% el año pasado.

Rentabilidad vs. Mercado: CANF obtuvo unos resultados inferiores a los del mercado IL, que fueron del 22.8% el año pasado.

Volatilidad de los precios

Is CANF's price volatile compared to industry and market?
CANF volatility
CANF Average Weekly Movement	8.1%
Biotechs Industry Average Movement	4.9%
Market Average Movement	4.0%
10% most volatile stocks in IL Market	7.3%
10% least volatile stocks in IL Market	2.9%

Precio estable de las acciones: El precio de las acciones de CANF ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de CANF(8%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de IL.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1994	8	Motti Farbstein	www.canfite.com

Can-Fite BioPharma Ltd., empresa biofarmacéutica en fase clínica, desarrolla en Israel productos terapéuticos de moléculas pequeñas biodisponibles por vía oral para el tratamiento del cáncer, las enfermedades inflamatorias del hígado y la disfunción eréctil. El principal candidato a fármaco de la empresa es el Piclidenoson, cuyo ensayo clínico de fase III se ha completado para el tratamiento de la psoriasis. Desarrolla Namodenoson, que está en fase III de ensayo clínico para el tratamiento del cáncer de hígado; y en fase IIa para el tratamiento del cáncer de páncreas; así como en fase IIb de ensayo para el tratamiento de la esteatohepatitis asociada al metabolismo; y CF602, que está en ensayo preclínico para el tratamiento de la disfunción eréctil.

Resumen de fundamentos de Can-Fite BioPharma Ltd.

¿Cómo se comparan los beneficios e ingresos de Can-Fite BioPharma con su capitalización de mercado?
Estadísticas fundamentales de CANF
Capitalización bursátil	₪53.15m
Beneficios(TTM)	-₪27.36m
Ingresos (TTM)	₪2.48m

21.5x

Ratio precio-ventas (PS)

-1.9x

Ratio precio-beneficio (PE)

¿Está CANF sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de CANF
Ingresos	US$667.00k
Coste de los ingresos	US$0
Beneficio bruto	US$667.00k
Otros gastos	US$8.04m
Beneficios	-US$7.37m

Últimos beneficios comunicados

Jun 30, 2024

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-0.0036
Margen bruto	100.00%
Margen de beneficio neto	-1,105.10%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado CANF a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción CANF

Recompensas

Análisis de riesgos

Competidores de Can-Fite BioPharma Ltd.

TASE:EVGN

₪32.5m

TASE:KMDA

₪1.3b

TASE:BLRX

₪128.4m

TASE:UNVO

₪2.8m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Can-Fite BioPharma Ltd. Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial

Can-Fite BioPharma Ltd.'s Partner Vetbiolix Reports Positive Results in Dog Osteoarthritis Study with Piclidenoson

Can-Fite BioPharma Ltd. Receives Approval from Israeli Ministry of Health to Conduct Phase IIa Clinical Trial with Orally-Administered Namodenoson in Treatment of Pancreatic Carcinoma

New major risk - Shareholder dilution

Insufficient new directors

First half 2024 earnings released: US$0.002 loss per share (vs US$0.004 loss in 1H 2023)

Recent updates

Can-Fite BioPharma Ltd. Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial

Can-Fite BioPharma Ltd.'s Partner Vetbiolix Reports Positive Results in Dog Osteoarthritis Study with Piclidenoson

Can-Fite BioPharma Ltd. Receives Approval from Israeli Ministry of Health to Conduct Phase IIa Clinical Trial with Orally-Administered Namodenoson in Treatment of Pancreatic Carcinoma

New major risk - Shareholder dilution

Insufficient new directors

First half 2024 earnings released: US$0.002 loss per share (vs US$0.004 loss in 1H 2023)

Can-Fite BioPharma Ltd. Announces Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson

Can-Fite BioPharma Ltd. Announces Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Vetbiolix

Can-Fite Announces Breakthrough Findings Demonstrate Namodenoson Anti-Cancer and Protective Effect Mechanism in the Liver

It's Unlikely That Can-Fite BioPharma Ltd.'s (TLV:CANF) CEO Will See A Huge Pay Rise This Year

Can-Fite Biopharma Ltd. Receives IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study

Can-Fite Biopharma Ltd. Updates on Its Advanced Liver Cancer Pivotal Phase 3 Study

Can-Fite BioPharma Ltd., Annual General Meeting, Jun 26, 2024

New minor risk - Share price stability

Can-Fite BioPharma Ltd. Announces FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study

Can-Fite BioPharma Ltd. Receives Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602

No longer forecast to breakeven

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Can-Fite BioPharma Ltd. Reports New Data on Namodenoson’s Anti-Obesity Mechanism of Action

Can-Fite BioPharma Ltd. Receives Positive Response from U.S. Food and Drug Administration on Pediatric Study Plan for Treatment of Children Suffering from Psoriasis with Piclidenoson

Can-Fite BioPharma Ltd. Completes the Design of a Phase IIa Study Protocol for the Treatment of Pancreatic Cancer Patients

Third quarter 2023 earnings released: US$0.001 loss per share (vs US$0.003 loss in 3Q 2022)

Can-Fite Biopharma Ltd. Announces Complete Response and 6.9 Years Overall Survival in A Patient with Advanced Liver Cancer Treated with Namodenoson

Can-Fite Biopharma Ltd. Provides Business Update

Can-Fite Biopharma Ltd. Announces Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal

New minor risk - Share price stability

New major risk - Market cap size

New major risk - Financial data availability

First half 2023 earnings released: US$0.004 loss per share (vs US$0.006 loss in 1H 2022)

Can-Fite Enters Rare Genetic Disease Field Based on Impactful Findings of A Fondazione Telethon and Naples University Researcher Showing Piclidenoson Is Efficacious in Treating Lowe Syndrome

Can-Fite Biopharma Ltd. Submits Pediatric Plan to U.S. Food and Drug Administration to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis

New major risk - Revenue and earnings growth

No longer forecast to breakeven

Can-Fite Biopharma Ltd. Receives U.S. FDA's Go Ahead for Piclidenoson Psoriasis Registration Plan

Can-Fite BioPharma Ltd., Annual General Meeting, Jul 31, 2023

Can-Fite BioPharma Ltd. to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson

First quarter 2023 earnings released: US$0.002 loss per share (vs US$0.003 loss in 1Q 2022)

Can-Fite BioPharma Ltd. to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

No longer forecast to breakeven

No longer forecast to breakeven

Can-Fite Biopharma Ltd. Announces Namodenoson Is Approved for Compassionate Use in the Treatment of Liver Cancer in Israel and Romania

Third quarter 2022 earnings released: US$0.003 loss per share (vs US$0.006 loss in 3Q 2021)

Can-Fite BioPharma Ltd. Announces Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies

Can-Fite BioPharma Ltd. Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; U.S. Food and Drug Administration Submission to Follow

Can-Fite Biopharma Ltd Provides Update on Its Clinical Program for Namodenoson in the Treatment of Hepatocellular Carcinoma

Third quarter 2022 earnings released: US$0.003 loss per share (vs US$0.006 loss in 3Q 2021)

Insufficient new directors

Can-Fite BioPharma Ltd.: New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy Presented by KOL Dr. Papp at the 31st European Academy of Dermatology

Second quarter 2022 earnings released: US$0.003 loss per share (vs US$0.006 loss in 2Q 2021)

Forecast to breakeven in 2023

Can-Fite BioPharma Ltd’s Drug Namodenoson Approves for Compassionate Use Treatment of Advanced Liver Cancer Patients in Romania

Can-Fite BioPharma Ltd. Reports Progress in the Development of Piclidenoson for Osteoarthritis in Pets Through Its Partner Vetbiolix

Can-Fite BioPharma Ltd., Annual General Meeting, Aug 29, 2022

Can-Fite BioPharma Ltd. to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis

Can-Fite BioPharma Ltd. Announces Positive Top-Line Results from Piclidenoson Phase III COMFORT Study in Moderate to Severe Psoriasis

Is Can-Fite BioPharma (TLV:CANF) In A Good Position To Invest In Growth?

First quarter 2022 earnings released: US$0.003 loss per share (vs US$0.004 loss in 1Q 2021)

Can-Fite BioPharma Ltd. Receives Key NASH Patent in Israel